Butocrolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C19H23NO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F63SY70KV0, chemically known as 9-(3-(tert-butylamino)-2-hydroxypropoxyl)-4-hydroxy-7-methyl-5h-furo(3,2-g)(1)benzopyran-5-one. but generally known as butocrolol, which bears US NIH Compound Identifier 189906. European Medicines Agency schedules Butocrolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06027MIG. The term BUTOCROLOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). BUTOCROLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butocrolol under HS 29329985 and SITC 51569. As of Q4 2014, BUTOCROLOL remains the US FDA Preferred Term for this commodity. Butocrolol bears US NLM identifiers UMLS ID C2698579 and NCI Concept Code C77939. SMILES: O(CC(O)CNC(C)(C)C)C1C2OC(CC(=O)C2C(O)C2C1OCC2)C.